Drug Trial Radar · NCT04410133
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Oct 26, 2020
Primary completion
Jun 5, 2023
Study completion Jun 5, 2023
Sponsor
- Lead sponsor
- Blue Earth DiagnosticsIndustry
- Sponsor type
- Industry
- Collaborators
- Precision For Medicine
- First posted
- Jun 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy
Conditions
- Brain Metastases
Interventions
18F fluciclovineDrug
18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject LevelTime frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
St. Joseph's Hospital and Medical Center
Phoenix, Arizona
University of California, San Francisco
San Francisco, California
John Wayne Cancer Institute at Providence St. John's Health Center
Santa Monica, California
Yale School of Medicine
New Haven, Connecticut
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Medical College of Georgia, Augusta University
Augusta, Georgia
Ochsner Clinic Foundation
New Orleans, Louisiana
Johns Hopkins Hospital
Baltimore, Maryland
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
Washington University School of Medicine-Center for Clinical Imaging Research
St Louis, Missouri
NYU Langone Health
New York, New York
University Hospital Cleveland
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Pennsylvania Health System
Philadelphia, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
Center for Quantitative Cancer Imaging at Huntsman Cancer Institute
Salt Lake City, Utah
West Virgina University Cancer Institute
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.